WO2003041698A1 - Comprimes contenant des acides amines se desintegrant rapidement dans la cavite buccale et procede de fabrication de ces comprimes - Google Patents
Comprimes contenant des acides amines se desintegrant rapidement dans la cavite buccale et procede de fabrication de ces comprimes Download PDFInfo
- Publication number
- WO2003041698A1 WO2003041698A1 PCT/JP2002/011769 JP0211769W WO03041698A1 WO 2003041698 A1 WO2003041698 A1 WO 2003041698A1 JP 0211769 W JP0211769 W JP 0211769W WO 03041698 A1 WO03041698 A1 WO 03041698A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- night
- group
- rapidly disintegrating
- amino acid
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 87
- 210000000214 mouth Anatomy 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 49
- 239000008187 granular material Substances 0.000 claims abstract description 51
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 239000011230 binding agent Substances 0.000 claims abstract description 31
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 238000000748 compression moulding Methods 0.000 claims abstract description 8
- 239000003826 tablet Substances 0.000 claims description 114
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 89
- 239000000047 product Substances 0.000 claims description 26
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 25
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 25
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 25
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 24
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 235000010356 sorbitol Nutrition 0.000 claims description 24
- 239000000600 sorbitol Substances 0.000 claims description 24
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 23
- 239000000845 maltitol Substances 0.000 claims description 23
- 235000010449 maltitol Nutrition 0.000 claims description 23
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 23
- 229940035436 maltitol Drugs 0.000 claims description 23
- 235000010355 mannitol Nutrition 0.000 claims description 22
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 21
- 229930195725 Mannitol Natural products 0.000 claims description 21
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 239000000594 mannitol Substances 0.000 claims description 21
- 239000000654 additive Substances 0.000 claims description 20
- 239000007884 disintegrant Substances 0.000 claims description 19
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 18
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 18
- 229960002920 sorbitol Drugs 0.000 claims description 18
- 239000004386 Erythritol Substances 0.000 claims description 17
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 17
- 235000019414 erythritol Nutrition 0.000 claims description 17
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 17
- 229940009714 erythritol Drugs 0.000 claims description 17
- 229960001855 mannitol Drugs 0.000 claims description 17
- 229940074410 trehalose Drugs 0.000 claims description 17
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 16
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 16
- 239000000811 xylitol Substances 0.000 claims description 16
- 235000010447 xylitol Nutrition 0.000 claims description 16
- 229960002675 xylitol Drugs 0.000 claims description 16
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 16
- 230000000996 additive effect Effects 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 14
- 229960003451 lactitol Drugs 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- 239000000832 lactitol Substances 0.000 claims description 13
- 235000010448 lactitol Nutrition 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 9
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000004570 mortar (masonry) Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 229960002160 maltose Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000007906 compression Methods 0.000 claims description 4
- 230000006835 compression Effects 0.000 claims description 4
- 229960001375 lactose Drugs 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000005461 lubrication Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000009940 knitting Methods 0.000 claims 2
- 125000003071 maltose group Chemical group 0.000 claims 2
- 239000012778 molding material Substances 0.000 claims 2
- 230000000153 supplemental effect Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940107161 cholesterol Drugs 0.000 claims 1
- 229940102187 disintegrating oral tablet Drugs 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 72
- 235000001014 amino acid Nutrition 0.000 description 72
- -1 lactitole Chemical compound 0.000 description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 235000014113 dietary fatty acids Nutrition 0.000 description 11
- 239000000194 fatty acid Substances 0.000 description 11
- 229930195729 fatty acid Natural products 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 239000007891 compressed tablet Substances 0.000 description 10
- 229960000310 isoleucine Drugs 0.000 description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- 239000000314 lubricant Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 229960003136 leucine Drugs 0.000 description 8
- 238000012858 packaging process Methods 0.000 description 8
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 235000004554 glutamine Nutrition 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
- 229960000913 crospovidone Drugs 0.000 description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000288140 Gruiformes Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 229960001230 asparagine Drugs 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000009429 distress Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 241000209219 Hordeum Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- MCRNHLQVPJEMSQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] MCRNHLQVPJEMSQ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 101710095911 Protein yippee-like 1 Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JJVXHDTWVIPRBZ-VKHMYHEASA-N (2r)-2-[carboxy(methyl)amino]-3-sulfanylpropanoic acid Chemical compound OC(=O)N(C)[C@@H](CS)C(O)=O JJVXHDTWVIPRBZ-VKHMYHEASA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 229910000906 Bronze Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000010974 bronze Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- IMTMXTBHGOKGLA-UHFFFAOYSA-N dodecyl hydrogen sulfate;sulfuric acid Chemical compound OS(O)(=O)=O.CCCCCCCCCCCCOS(O)(=O)=O IMTMXTBHGOKGLA-UHFFFAOYSA-N 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- GHCFSEYUTLFJQU-UHFFFAOYSA-M sodium;carboxymethyl sulfate Chemical compound [Na+].OC(=O)COS([O-])(=O)=O GHCFSEYUTLFJQU-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Definitions
- the present invention relates to an intraoral fiber containing a large amount of amino acids and its si method.
- Difficult as an amino acid-based product or as an auxiliary food, there are known sports drinks in which amino acid is dissolved in water, jelly containing amino acids, and mixed granules of amino acid that can be taken with water. .
- Oral tablets consisting of water-soluble azulene, L-glutamine, break-through ij, charcoal rooster and disgusting stomach-causing agents have already been proposed in the pharmaceutical field as an oral repellent containing amino acids.
- Japanese Unexamined Patent Publication No. 2000-26686 Japanese Unexamined Patent Publication No. 2000-26686.
- gurumin disclosed in Japanese Patent Application Laid-Open No. 2000-26286, if saliva is formed in the oral cavity, charcoal ⁇ S salt is decomposed and carbonic acid gas is released.
- Generating (C 02 gas) hinders the disintegration of the fiber IJ. Since it is a so-called effervescent tablet, there is irritation in the oral cavity.
- a lubricant such as magnesium stearate, sulfuric acid lauryl sulfate, modified sodium, talc, etc., is kneaded in addition to the grease, and the ffi-condensed mixture is subjected to so-called internal lubrication, which is called TO.
- TO internal lubrication
- the usual oral administration fabric II requires drinking with water and is difficult to drink during jogging, which is inconvenient as a sporting product.
- the material in order to make a key drug for oral administration, the material must be compressed and molded under considerable pressure, and there is a problem with the stability of some amino acids such as glumin.
- the present invention relates to a preparation containing an amino acid, which, when contacted with saliva in the oral cavity, rapidly disintegrates and does not require water when taken.
- Another object of the present invention is to provide a rapid oral disintegration in which various amino acids are uniformly dispersed in a recording agent, and a method for producing the same.
- Another object of the present invention is to provide a preparation containing an amino acid as a product, and to perform an intraoral injection method excellent in the stability of the amino acid.
- Another object of the present invention is to provide a preparation containing an amino acid as the following, which has a short disintegration time in the oral cavity and its S3 ⁇ 4g method.
- the present invention also provides a fiber iJ containing an amino acid as a main ingredient, which is hardly chipped even when an external force is applied during storage, and which provides an intraoral pot and its S3 ⁇ 4i method.
- the purpose is.
- Another object of the present invention is to provide an oral cavity containing an amino acid which does not contain an effervescent component in the tablet and which is less irritating to the oral cavity, and an SII method thereof.
- the oral conversion described in claim 1 is characterized in that the oral conversion is lactose, maltose, trehalose, sorbitole, lactitoleone, mannitol, erythritol, xylitol and maltitol, and glycated ⁇ J, amino acid and amino acid. It includes one selected from the group consisting of derivatives and a disintegrant.
- the rapid oral disintegration according to claim 2 is characterized in that a mixture containing one selected from the group consisting of an amino acid and an amino acid derivative and a disintegrant is granulated using a binder water intense night and dried. It is obtained by compressing the obtained granules.
- the rapid oral disintegration of the oral cavity according to claim 3 is characterized in that a mixture containing one selected from the group consisting of amino acids and amino acid derivatives and a disintegrant is granulated by using an agitated water intense night. (It consists of a mixture of the granulated material obtained by the above and an additive.) ⁇ It is obtained by compressing the excipient.
- the rapidly disintegrating buccal tablet according to claim 4 is characterized in that the binder water sickle is a water sickle according to claim 2 or claim 3. It is a certain rapidly disintegrating tablet in the mouth.
- the oral water conversion in claim 2 or in the oral claim described in claim 3 is carried out, and the binder water intense night is Maltos water intense night.
- a KB agent selected from the group consisting of xylitol, maltitol and lactose.
- the intra-oral fast decay seam according to claim 8 may be a pharmaceutical, a rye-yeo product or an escort food, wherein the intra-oral fast decay according to any one of claims 1 to 7 is used.
- the $ 3 ⁇ 4t method of oral distress described in claim 12 is a binder used in the iSi method of oral distress described in claim 10 or claim 11. This is a method for producing an orally rapidly disintegrating tablet in which the aqueous solution is a lactose aqueous solution.
- the method for difficulties in the oral cavity according to claim 13 is a binder used in the method for rapid intra-oral collapse according to claim 10 or claim 11.
- Water ⁇ night power Maltose water ⁇ night, trehalose water night, sorbitol water ⁇ night, erythritol water ⁇ , xylitol aqueous solution, lactitol aqueous solution, mannitol water, benite water, maltitol water Water selected from the group consisting of night ⁇ This is a method for producing a rapidly disintegrating tablet in the oral cavity at night.
- the SSg method of the oral cavity sea according to claim 14 is an additive used in the S ⁇ g method of the oral fiber according to any one of claims 11 to 13. Is a method for producing a rapidly disintegrating tablet in the oral cavity, which comprises a blinding agent selected from the group consisting of trueno, loin, mannitol, erythritol, lactitole, maltitol, xylitol, sorbitol and 3 ⁇ 4 ⁇ .
- the intra-oral S3 ⁇ 4g method according to claim 15 is a method for compressing and expanding the intra-oral distress S3 ⁇ 4g method according to any one of claims 9 to 14. , Lubrication »using a pestle, mortar, etc. 3 ⁇ 4i method.
- the S3 ⁇ 4g method of intraoral complaint according to claim 16 is the method of intraoral 3 ⁇ 4H species according to any one of claims 9 to 15! ⁇ I ⁇ t by way of mouth
- the inside of the cavity is a method for producing oral rapid disintegration, which is a drug, a specialty product or a food supplement.
- the oral cavity according to claim 17 is a sugar compound selected from the group consisting of 3 ⁇ 4 ⁇ , maltose, trehalose, sorbitol and maltitol, and a group consisting of amino acid and amino acid derivatives. Contains one selected and a disintegrant.
- the rapid oral collapse in the oral cavity according to claim 18 is characterized in that a mixture containing one selected from the group consisting of amino acids and amino acid derivatives and disintegration IJ is granulated using a binder water. The granules obtained by drying are obtained by compression molding.
- the oral distress according to claim 19, wherein the mixture containing one selected from the group consisting of an amino acid and an amino acid derivative and a breakup IJ is granulated using a binder water intense night. It is obtained by compression molding a release material consisting of a granulated product obtained by mixing with an additive ⁇ ).
- the binder aqueous solution of the rapidly disintegrating tablet in oral cavity according to claim 18 or 19 is an aqueous lactose solution.
- the intraoral quick-disintegrating method according to claim 21 is the method for converting into the oral cavity according to claim 18 or claim 19. It is an aqueous solution selected from the group consisting of trehalose water intense nights, sorbitol water intense nights, and maltitol water intense nights.
- the intraorally fast disintegrating tablet according to any one of claims 17 to 22 is an external lubricating tablet.
- the rapidly disintegrating tablet in oral cavity according to any one of claims 17 to 23 is a pharmaceutical, a nutritional food or a dietary supplement.
- the S3 ⁇ 4t method for intraoral occupation according to claim 26 includes the steps of preparing a konk J containing one selected from the group consisting of amino acids and amino acid derivatives and decay. Granulate using granulated water and intense night, and dry to form granules: ⁇ -presentation and compression molding of granules are provided.
- a mixture containing one selected from the group consisting of amino acids and amino acid derivatives and a disintegrant is prepared.
- the mixture is granulated using a binder water intense night, dried and granulated, and the granulated material is mixed with additives to prepare a sword material. And a step of ffi crunching the material.
- the method of releasing the intraoral swollen sea according to claim 29 is used in the S ⁇ method of intraorally hazy as described in claim 26 or 27, wherein the binder water However, it is an aqueous solution selected from the group consisting of maltose water ⁇ night, trenourous water benvenor, sorbitol water, and generally multi-tol water.
- the SSt ⁇ method of intraoral conversion described in claim 30 is an additive used in the method of intraoral patronization described in any of claims 27 to 29. However, it contains a supplement agent selected from the group consisting of trehalose, mannitol and 3 ⁇ 4 ⁇ .
- the S ⁇ method of intraoral reversal according to claim 31 is a method of observing intraoral discomfort according to any one of claims 25 to 30;
- the process is characterized by using a punch and a sun coated with a lubricant.
- the orally rapidly disintegrating tablet which is obtained by the method of the oral cavity in the oral cavity according to any one of claims 25 to 31, is a medicine, a nutritional food or a dietary supplement.
- BEST MODE FOR CARRYING OUT THE INVENTION The amino acids used in the present invention include, for example, amino acids such as glycine and alanine, branched amino acids such as norin, leucine and isoleucine, hydroxyamino acids such as serine and threonine, aspartic acid, and glutamine.
- Amides such as acidic amino acids, asparagine and glutamine; basic amino acids such as lysine, hydroxylysine, arginine and ordinine; sulfur-containing amino acids such as cystine, cystine and methionine; and aromatics such as phenylalanine and tyrosine Examples include amino acids, amino acids such as tributofan and histidine, or imino acids such as proline and 4-hydroxyproline.
- amino acid derivatives include, for example, acetyl glumin, acetyl cysteine, carboxymethyl cysteine, acetyl thyrocis acetyl hydroxyproline, 5-hydroxyproline, glucanthione, creatine, S-adenylmethionine, glycylglycine Glycylglutamine, DOPA, aranylglutamine, carnitine and the like.
- amino acids used in the present invention preferred are amino acids such as norin, leucine and isoleucine, amides such as asparagine and glutamine, and virgin amino acids such as iris hydroxylidine and arginis orditin.
- Branched amino acids such as leucine and isoleucine or amides such as asparagine and glutamine are more preferred.
- Particularly preferred amino acids include valisleucine, isoleucine, glutamine and arginine.
- Branched chain amino acids such as valine, leucine and isoleucine or amides such as asparagine and glutamine have a solubility in water at 25 ° C of 0.5% or more and 10% or less.
- the intraoral rapidly degradable species of the present invention contains an amino acid or an amino acid derivative # (a book may be contained in combination with a job or ⁇ 6.
- the combination of amino acids or amino acid derivatives ⁇ is not particularly limited. And two or more selected from the group consisting of amino acids and amino acid derivatives can be used in any combination.
- a combination of two or more amino acids selected from the group consisting of Sadashima Tadashi amino acids, amides and experimental amino acids is preferred.
- hazy amino acid combinations include valine, leucine and isoleucine
- Three types of branched amino acids ⁇ include Gluminamine and one or more types of amino acids ⁇ Arginine and one or more types of amino acids
- These groups ⁇ : may be further combined with other types of amino acids.
- amino rooster during the rapid intraoral collapse test, but preferably 20 to 98% by weight, more preferably 35 to 95% by weight, and 50 to 93% by weight. Is particularly preferred.
- Preferred disintegrants are crospovidone, croscarmellose sodium, low-molecular-weight S hydroxypropylcellulose, carboxymethylcellulose, calcium carboxymethylcellulose, and sodium carboxymethylsulfate.
- ijfcR amino acids such as proline, arginis ordinine, lysine, and glycine can be used as colloids by blending them in an amount of 5 to 15%.
- the disintegrant is S3 ⁇ 4g during oral hearing, 1 ⁇ 30% by weight, preferably! To 15% by weight, more preferably 1 to: L 0% by weight.
- two or more disintegrants may be contained.
- water intensity of the binder water there is no particular limitation on the water intensity of the binder water, but water such as teK alone can be used alone, but a water scythe containing vinegar is preferred.
- the syrup examples thereof include lactose, maltose, trenolulose, sorbitol, lactitol, mannitol, erythritol, xylitol and maltitol.
- the amount of maltose, trehalose, sorbitol, lactitol, mannitol, erythritol, xylitol or maltitol used as a ⁇ agent is preferably 1 to 30% by weight, preferably 1 to 20% by weight per tablet in the oral cavity. % By weight is more preferable, and 1 to 10% by weight is particularly preferable.
- powders can be added in the form of a powder, but it is preferable to use the aqueous solution obtained by dissolving in water as a binder, and to add them to the key material.
- the amount of ⁇ in the midnight of the aqueous solution is not particularly limited, but is preferably 0.5 to 20% by weight, more preferably 2 to 15% by weight, and particularly preferably 5 to 10% by weight.
- Gaku I by itself, It is soluble in water, but has low viscosity even when dissolved in water.
- an additive may be added.
- the additive may be added to any of the steps iii of the rapid oral disintegration of the present invention.
- the additive may be used as a mixture with a mixture containing an amino acid and a disintegrant, and You may mix and use the mixture containing a disintegrant with the granulated material obtained by granulating.
- the additives are not particularly limited as long as they are components that can be added to pharmaceuticals, praised goods, and praise foods.
- Coating agent, m sweetener, flavoring agent, Fluidizers and mi agents are components that can be added to pharmaceuticals, praised goods, and praise foods.
- Coating agent, m sweetener, flavoring agent, Fluidizers and mi agents are components that can be added to pharmaceuticals, praised goods, and praise foods.
- m sweetener m sweetener
- flavoring agent flavoring agent
- Fluidizers and mi agents.
- each is preferably from 20 to 20% by weight, and more preferably from 0.1 to 10% by weight.
- nutrients include reduced glucose, which is a quantitative sugar, oligosaccharide, a dextrin sugar, cyclodextrin, a bitter corrector, food pigments such as beta-carotene, niacin, vitamin ⁇ , Ascorbic acid, vitamin Bl, bimin ⁇ 2, vitamins; vitamins such as ⁇ 6, vitamin ⁇ 12, vitamins such as vitamin ⁇ , bimin D, minerals such as sodium, Nicotinamide, calcium pantothenate, folic acid and the like.
- ⁇ indicates that the surface is made of cellulose (eg, hydroxypropylmethylcellulose phthalate (HPMCP), acrylic (eg, methacrylic acid copolymer), natural Coating with a coating agent such as a system (for example, ceramic) may be used to mask bitterness.
- HPMCP hydroxypropylmethylcellulose phthalate
- acrylic eg, methacrylic acid copolymer
- a coating agent such as a system (for example, ceramic) may be used to mask bitterness.
- sweetener and flavoring agent for example, sucralose, aspartame, glucose, Fructose, saccharin and the like.
- agent examples include food colors such as petacarotene, yellow iron sesquioxide, and red iron sesquioxide.
- sucrose fatty acid ester sucrose fatty acid ester, nayone oil and fat powder, talc, light ifck keic acid, calcium silicate, synthetic aluminum silicate, steer
- examples include magnesium phosphate, calcium stearate, and stearyl sodium fumarate.
- stock agent examples include trehalose, mannitol, sorbitol, erythritol, lactitol, xylitol, maltitol, lactose, and the like.
- the rapid oral disintegration according to the present invention may contain IJ in the area, but if the tablet contains lubricated
- Stearic acid, magnesium stearate / calcium stearate, and other stearic acid salts, stearyl sodium fumarate, sucrose fatty acid, talc, oilseed rape and the like are preferable to use lubricants described in Japan Tsurugata, official food additives, etc., as lubricating oils used for foods and food supplements.
- the oral cavity of the oral cavity contains lactose, maltose, trehalose, lactitol, mannitol, erythritol, xylitol, sorbitol and maltitol.
- the rapid intraoral disintegration of the present invention is produced by compressing a granulated product obtained by granulating a mixture containing an amino acid and
- the binder can be dissolved in water such as teK and the like, and the melting angle can be determined without any particular limitation. However, it is preferably 40 to 100 ° C, and 50 to 9 ° C. 5 ° C is preferred, 60-90 ° C. is particularly preferred.
- Granulation is not particularly limited, but is preferably from 40 to 100 ° C, more preferably from 40 to 95 ° C, and particularly preferably from 50 to 90 ° C.
- ⁇ using 3 ⁇ 41 as a binding agent is used to convert between amino tick, tachiko and amino ⁇ ! ⁇ Crystals are likely to be formed in the binding agent (lactose), which is thought to exert shape retention against external physical forces.
- iceless milk crystal exists in the oral cavity using the water intense night of the present invention. It can be confirmed by the described X-ray diffraction method or the like.
- the drying method is not particularly limited, and examples thereof include fluidized bed drying and sculpture, and difficulties. Although there is no particular limitation on the song, it is preferably 40 to 100 ° (preferably, 50 to 95 ° C, more preferably 60 to 90 ° C).
- the method for producing ⁇ 3 ⁇ 4 is not particularly limited.
- it can be carried out using a 5-inch tablet machine.
- a punch and a device without a lubricating device can be used, but it is preferable to use a punch and a device with a lubricating device. Compression can be performed using a lubricated punch day or a lubricated punch and day.
- Binder water obtained by heating and dissolving 300 g of mannitol in 150 ° g of purified S3 ⁇ 4K at 65 ° C is stirred with a granulator (trade name: Vertical Granulator VG-2) Type 5 (manufactured by Ureki Co., Ltd.) and kneaded for about 3 minutes.
- a granulator trade name: Vertical Granulator VG-2
- Type 5 manufactured by Ureki Co., Ltd.
- the granulated product is granulated as above by using a fluidized bed ( ⁇ (trade name: FLO-5, manufactured from front soil)) at about 50 ° C for 15 minutes to obtain the granulated product. Obtained.
- the obtained granules were sized using a No. 28 wire mesh to obtain granules for tableting.
- a mouth-filled type punched fiber product name: AP-15, manufactured by Hata Iron Works
- sucrose fatty acid ester was used because of safety, considering that the intraoral job change performed by S ⁇ ⁇ i was used for resurrection goods or reciting food supplements. .
- the outline of the tablet pressed is shown below.
- the intra-oral fast-collapsing nada possessed practical hardness without damage to tablets during the packaging process after flow and tableting, and disintegrated quickly in the oral cavity.
- VG-25 manufactured by Nordek
- a 13 mm0 flat type ⁇ was attached to a mouth-to-tail type 1-strength fiber ( ⁇ -15 type, manufactured by Hata Tetsusho Co., Ltd.) equipped with a lubricant decoration device, and the mortar was filled with the beaten granules.
- a magnesium stearate was applied to the inner peripheral surface using a Rauley-type punching machine equipped with a device to apply magnesium stearate to the surface and the sun wall.
- the above-mentioned self-granulating granules are compressed with a 13 ⁇ 43 ⁇ 4 weight of about 720 mg at 20 kN to produce a rapidly disintegrating tablet in the oral cavity did.
- a 13 mm0 flat ⁇ is attached to the mouth-evening type fiber (AP-15 type, manufactured by Hata Iron Works) equipped with the cat U Wei device, and the fine granules are filled in the day.
- the magnesium stearate was applied to the upper surface on the day when the magnesium stearate was applied to the inner peripheral surface using a roller-type keying machine equipped with a device for applying magnesium stearate to the surface of the punch and the mortar wall.
- a roller-type keying machine equipped with a device for applying magnesium stearate to the surface of the punch and the mortar wall.
- the oral cavity had practical hardness without damage to the tablets during packaging of the barley and perforated barley, and disintegrated quickly in the oral cavity. Difficult case 4
- the granulated material was obtained by drying with warm air of about 80 ° C for 15 minutes.
- the obtained granules were sized with a No. 20 wire mesh to obtain granules for tableting.
- the sucrose fatty acid ester was applied to the inner surface of the pestle using a Royu-Ryi-type punching device equipped with a device to ⁇ The ester was applied, using the lower punch with sucrose fatty acid ester applied on the upper surface and the upper punch with sucrose fatty acid ester applied on the lower surface, and the inm granules mentioned above were converted into 2
- L-Kure-Yu-min (Kyowa Hakko Shiki Co., Ltd.) 500 g , orange flavor 55 g and crospovidone 270 g are mixed and stirred (Product name: Notical Granule Ichiichi VG-25 type) , Manufactured by Nordek Co., Ltd.) and kneaded for about 3 minutes. Then, 800% of a 20% aqueous solution of 1% was added to a stirring granulator (product name: Vertical Granule Uryu-Ichiichi VG-25 type, manufactured by Parex Co., Ltd.) and kneaded.
- a stirring granulator product name: Vertical Granule Uryu-Ichiichi VG-25 type, manufactured by Parex Co., Ltd.
- the extruded fiber product name: DGL-1 type, manufactured by Fuji Padal Co., Ltd.
- the extruded fiber was granulated. After that, granules were obtained by drying the product with »Kaisen (trade name: FLO-5, manufactured by Front Co., Ltd.) for 15 minutes at about 80 ° C.
- sucrose fatty acid ester was applied to the inner surface using a mouth-to-mouth type punching machine equipped with a device for applying sucrose fatty acid ester to the ft3 ⁇ 4 face and the sun wall. Mortar coated with sucrose fatty acid ester on the top, lower punch The above granules were compressed with a tableting pressure of 2 OkN) using an upper punch coated with a fatty acid ester of syrup, to produce rapidly disintegrating tablets in the oral cavity.
- Difficult Example 4 An orally rapidly disintegrating tablet was produced in the same manner as in Difficult Example 4 except that the component of the drug was changed to trehalose.
- Example 4 is different from Example 4 except that the component of the binder is changed to maltose.
- Difficult Example 4 An orally rapidly disintegrating tablet was produced in the same manner as in Difficult Example 4, except that the component of the binder was changed to sorbitol.
- Difficult Example 4 An intraoral quick disintegration key was produced in the same manner as in Difficult Example 4, except that the component of the drug was changed to maltitol.
- Sickle Example 2 rapid intraoral disintegration 13 ⁇ 4 was produced in the same manner as in Kenji Example 2, except that the agent was replaced with purified zK.
- Example 4 a rapidly disintegrating oral cavity was produced in the same manner as in Difficult Example 4, except that the component of the binder was changed to erythritol.
- a tablet containing an amino acid which disintegrates rapidly by invading saliva in the oral cavity and rapidly disintegrates, does not require water at the time of the month of the month, and a method for producing the same. Is done.
- the present invention also provides a rapidly disintegrating key in the oral cavity in which various amino acids are uniformly dispersed in a key material, and a method for producing the same.
- a rapidly disintegrating tablet in the oral cavity which is a preparation containing an amino acid as an ingredient and which is excellent in the stability of amino acid.
- a tablet containing an amino acid as a product a rapidly disintegrating tablet in the oral cavity having a short disintegration time in the oral cavity, and a method for producing the same.
- the present invention also provides an intraoral cavity and a method for producing the same, which is a preparation containing an amino acid, which is hardly chipped even when an external force is applied during storage or transportation. Further, the present invention provides a rapidly disintegrating tablet in the oral cavity containing an amino acid containing no essence and having little irritation to the oral cavity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02778095A EP1444978A1 (en) | 2001-11-13 | 2002-11-12 | Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
US10/250,863 US20040047904A1 (en) | 2001-11-13 | 2002-11-12 | Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same |
JP2003543585A JP4108605B2 (ja) | 2001-11-13 | 2002-11-12 | アミノ酸含有口腔内速崩壊錠及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001/347304 | 2001-11-13 | ||
JP2001347304 | 2001-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003041698A1 true WO2003041698A1 (fr) | 2003-05-22 |
Family
ID=19160326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/011769 WO2003041698A1 (fr) | 2001-11-13 | 2002-11-12 | Comprimes contenant des acides amines se desintegrant rapidement dans la cavite buccale et procede de fabrication de ces comprimes |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040047904A1 (ja) |
EP (1) | EP1444978A1 (ja) |
JP (1) | JP4108605B2 (ja) |
WO (1) | WO2003041698A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298373A (ja) * | 2004-04-08 | 2005-10-27 | Kyowa Hakko Kogyo Co Ltd | 吸水性アミノ酸含有糖衣錠剤 |
JP2006232680A (ja) * | 2005-02-22 | 2006-09-07 | Kyoto Pharmaceutical Industries Ltd | 錠剤用崩壊剤及びこれを用いた錠剤 |
JPWO2006080498A1 (ja) * | 2005-01-31 | 2008-06-19 | 協和醗酵工業株式会社 | オルニチン塩酸塩を含有する錠剤 |
WO2009084678A1 (ja) * | 2007-12-28 | 2009-07-09 | Sawai Pharmaceutical Co., Ltd. | 口腔内崩壊錠およびその製造方法 |
JP2010132626A (ja) * | 2008-12-08 | 2010-06-17 | Kyorin Pharmaceut Co Ltd | 口腔内速崩壊性錠剤 |
WO2011059075A1 (ja) * | 2009-11-13 | 2011-05-19 | 味の素株式会社 | グルタミン酸およびアルギニンの高含有製剤 |
WO2013125497A1 (ja) * | 2012-02-20 | 2013-08-29 | ニプロ株式会社 | 口腔内崩壊錠の製造方法 |
JP2013193974A (ja) * | 2012-03-19 | 2013-09-30 | Fancl Corp | アミノ酸高含有錠剤 |
WO2013161815A1 (ja) * | 2012-04-23 | 2013-10-31 | 味の素株式会社 | グルタミン酸及びアルギニン高含有錠剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004016262A1 (ja) * | 2002-08-12 | 2004-02-26 | Kyowa Hakko Kogyo Co., Ltd. | アミノ酸含有チュアブル錠 |
KR20060135022A (ko) * | 2004-04-14 | 2006-12-28 | 교와 핫꼬 고교 가부시끼가이샤 | 분기 사슬 아미노산을 함유하는 정제 및 그 제조 방법 |
US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US20060068009A1 (en) * | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
MA52957A (fr) * | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Procédés de fabrication de compositions d'acides aminés |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2088334A1 (en) * | 1992-01-29 | 1993-07-30 | Tadashi Makino | Fast dissolving tablet and its production |
WO1998053798A1 (en) * | 1997-05-27 | 1998-12-03 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation |
WO1999004758A1 (en) * | 1997-07-25 | 1999-02-04 | Elan Corporation Plc | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
WO2000006126A1 (en) * | 1998-07-28 | 2000-02-10 | Takeda Chemical Industries, Ltd. | Rapidly disintegrable solid preparation |
JP2000178182A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 崩壊性組成物 |
JP2000178183A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 固形製剤及びその製造方法 |
JP2000178184A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 粒状組成物、錠剤及び粒状組成物の製造方法 |
WO2000078292A1 (fr) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Preparations solides a desintegration rapide |
JP2002128661A (ja) * | 2000-10-20 | 2002-05-09 | Chugai Pharmaceut Co Ltd | 速崩壊錠剤の製造方法 |
JP2002154988A (ja) * | 2000-11-21 | 2002-05-28 | Taiyo Yakuhin Kogyo Kk | 口腔内崩壊錠剤およびその製造方法 |
JP2002188095A (ja) * | 2000-12-21 | 2002-07-05 | Fancl Corp | 植物性油脂粉末及び該粉末を含む食品組成物 |
JP2002308760A (ja) * | 2001-04-06 | 2002-10-23 | Taiyo Yakuhin Kogyo Kk | 圧縮成型用組成物及びその利用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887437A (en) * | 1956-08-22 | 1959-05-19 | Pfizer & Co C | Palatable vitamin tablet containing an amino acid |
JPS5614098A (en) * | 1979-07-13 | 1981-02-10 | Takeda Chem Ind Ltd | Externally lubricating tablet making machine |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5576014A (en) * | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
DE4444052A1 (de) * | 1994-12-10 | 1996-06-13 | Rhone Poulenc Rorer Gmbh | Pharmazeutische, oral anwendbare Zubereitung |
-
2002
- 2002-11-12 WO PCT/JP2002/011769 patent/WO2003041698A1/ja active Application Filing
- 2002-11-12 EP EP02778095A patent/EP1444978A1/en not_active Withdrawn
- 2002-11-12 US US10/250,863 patent/US20040047904A1/en not_active Abandoned
- 2002-11-12 JP JP2003543585A patent/JP4108605B2/ja not_active Expired - Lifetime
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2088334A1 (en) * | 1992-01-29 | 1993-07-30 | Tadashi Makino | Fast dissolving tablet and its production |
EP0553777A2 (en) * | 1992-01-29 | 1993-08-04 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
WO1998053798A1 (en) * | 1997-05-27 | 1998-12-03 | Takeda Chemical Industries, Ltd. | Solid pharmaceutical preparation |
WO1999004758A1 (en) * | 1997-07-25 | 1999-02-04 | Elan Corporation Plc | A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets |
WO2000006126A1 (en) * | 1998-07-28 | 2000-02-10 | Takeda Chemical Industries, Ltd. | Rapidly disintegrable solid preparation |
JP2000178182A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 崩壊性組成物 |
JP2000178183A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 固形製剤及びその製造方法 |
JP2000178184A (ja) * | 1998-12-17 | 2000-06-27 | Lion Corp | 粒状組成物、錠剤及び粒状組成物の製造方法 |
WO2000078292A1 (fr) * | 1999-06-18 | 2000-12-28 | Takeda Chemical Industries, Ltd. | Preparations solides a desintegration rapide |
JP2002128661A (ja) * | 2000-10-20 | 2002-05-09 | Chugai Pharmaceut Co Ltd | 速崩壊錠剤の製造方法 |
JP2002154988A (ja) * | 2000-11-21 | 2002-05-28 | Taiyo Yakuhin Kogyo Kk | 口腔内崩壊錠剤およびその製造方法 |
JP2002188095A (ja) * | 2000-12-21 | 2002-07-05 | Fancl Corp | 植物性油脂粉末及び該粉末を含む食品組成物 |
JP2002308760A (ja) * | 2001-04-06 | 2002-10-23 | Taiyo Yakuhin Kogyo Kk | 圧縮成型用組成物及びその利用 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298373A (ja) * | 2004-04-08 | 2005-10-27 | Kyowa Hakko Kogyo Co Ltd | 吸水性アミノ酸含有糖衣錠剤 |
JP2012121925A (ja) * | 2005-01-31 | 2012-06-28 | Kyowa Hakko Bio Co Ltd | オルニチン塩酸塩を含有する錠剤 |
JPWO2006080498A1 (ja) * | 2005-01-31 | 2008-06-19 | 協和醗酵工業株式会社 | オルニチン塩酸塩を含有する錠剤 |
JP5014115B2 (ja) * | 2005-01-31 | 2012-08-29 | 協和発酵バイオ株式会社 | オルニチン塩酸塩を含有する錠剤 |
JP2006232680A (ja) * | 2005-02-22 | 2006-09-07 | Kyoto Pharmaceutical Industries Ltd | 錠剤用崩壊剤及びこれを用いた錠剤 |
WO2009084678A1 (ja) * | 2007-12-28 | 2009-07-09 | Sawai Pharmaceutical Co., Ltd. | 口腔内崩壊錠およびその製造方法 |
JP5352474B2 (ja) * | 2007-12-28 | 2013-11-27 | 沢井製薬株式会社 | 口腔内崩壊錠およびその製造方法 |
US9314454B2 (en) | 2007-12-28 | 2016-04-19 | Sawai Pharmaceutical Co., Ltd. | Oral cavity disintegrating tablet and method of producing the same |
JP2010132626A (ja) * | 2008-12-08 | 2010-06-17 | Kyorin Pharmaceut Co Ltd | 口腔内速崩壊性錠剤 |
WO2011059075A1 (ja) * | 2009-11-13 | 2011-05-19 | 味の素株式会社 | グルタミン酸およびアルギニンの高含有製剤 |
WO2013125497A1 (ja) * | 2012-02-20 | 2013-08-29 | ニプロ株式会社 | 口腔内崩壊錠の製造方法 |
JPWO2013125497A1 (ja) * | 2012-02-20 | 2015-07-30 | ニプロ株式会社 | 口腔内崩壊錠の製造方法 |
JP2013193974A (ja) * | 2012-03-19 | 2013-09-30 | Fancl Corp | アミノ酸高含有錠剤 |
WO2013161815A1 (ja) * | 2012-04-23 | 2013-10-31 | 味の素株式会社 | グルタミン酸及びアルギニン高含有錠剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2003041698A1 (ja) | 2005-03-03 |
JP4108605B2 (ja) | 2008-06-25 |
EP1444978A1 (en) | 2004-08-11 |
US20040047904A1 (en) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2184570C2 (ru) | Препараты для орального введения | |
JP5537943B2 (ja) | 速崩壊性固形製剤 | |
WO2003041698A1 (fr) | Comprimes contenant des acides amines se desintegrant rapidement dans la cavite buccale et procede de fabrication de ces comprimes | |
SA99191111A (ar) | طريقة لتصنيع أقراص تنتشر بالمضغ | |
JP2001510785A (ja) | 速崩壊性口内溶解錠の製造に適した顆粒の製造方法 | |
JP5342028B2 (ja) | 口腔内崩壊錠 | |
JP5198065B2 (ja) | ジペプチド含有経口用組成物 | |
JPH093071A (ja) | S(+)−エトドラクの経口製剤 | |
EP1604659B1 (en) | Tablet containing water-absorbing amino acid | |
JPWO2004016262A1 (ja) | アミノ酸含有チュアブル錠 | |
JP4689468B2 (ja) | 錠剤およびその製造方法 | |
JP4501024B2 (ja) | システイン類の苦味及び臭気が軽減された組成物 | |
JP2002029964A (ja) | 固形医薬組成物 | |
JP2004269384A (ja) | 吸水性アミノ酸被覆顆粒 | |
EP1738755B1 (en) | Tablet containing branched chain amino acid and process for producing the same | |
JP3778240B2 (ja) | 不快な味がマスキングされた造粒組成物及びその製造方法 | |
JP5527921B2 (ja) | 苦味を隠蔽した経口固形組成物 | |
JP2005060309A (ja) | 不快な味を低減した口腔内崩壊錠剤 | |
CN105555316B (zh) | 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂 | |
JP4501023B2 (ja) | システイン類の苦味及び臭気が軽減された組成物 | |
JP6655351B2 (ja) | 造粒物及びこれを含む経口製剤並びに造粒物及び経口製剤の製造方法 | |
JP7093534B2 (ja) | ヨクイニンを含むプレミックスエキス及びその利用 | |
JP2005029557A (ja) | 口腔内速崩壊性錠剤およびその製造方法 | |
JP5467787B2 (ja) | 経口用固形組成物 | |
JP7296198B2 (ja) | 医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002778095 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003543585 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10250863 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002778095 Country of ref document: EP |